Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib

References

• Adjei AA, Schwartz B, Garmey E. (2011). Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 16:788–99.
   PubMed Web of Science ®Google Scholar
• Allali-Hassani A, Peralba JM, Martras S, et al. (1998). Retinoids, omega-hydroxyfatty acids and cytotoxic aldehydes as physiological substrates, and H2-receptor antagonists as pharmacological inhibitors, of human class IV alcohol dehydrogenase. FEBS Lett 426:362–6.
   PubMed Web of Science ®Google Scholar
• Baraona E, Abittan CS, Dohmen K, et al. (2001). Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 25:502–7.
   PubMed Web of Science ®Google Scholar
• Barter ZE, Tucker GT, Rowland-Yeo K. (2013). Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modeling. Clin Pharmacokinet 52:1085–100.
   PubMed Web of Science ®Google Scholar
• Battiston L, Tulissi P, Moretti M, Pozzato G. (1997). Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine. Pharmacol Toxicol 81:247–52.
   PubMedGoogle Scholar
• Edenberg HJ. (2000). Regulation of the mammalian alcohol dehydrogenase genes. Prog Nucleic Acid Res Mol Biol 64:295–341.
   PubMed Web of Science ®Google Scholar
• Edenberg HJ. (2007). The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 30:5–13.
   PubMedGoogle Scholar
• Haas S, Merkelbach-Bruse S, Justenhoven C, et al. (2009). Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver. Pathol Res Pract 205:716–25.
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Hamamoto Y, et al. (2004). Altered levels of cytochrome P450 genes in hepatitis B or C virus-infected liver identified by oligonucleotide microarray. Cancer Genomics Proteomics 1:53–8.
   Google Scholar
• Jelski W, Zalewski B, Szmitkowski M. (2008). The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer. Dig Dis Sci 53:2550–5.
   PubMed Web of Science ®Google Scholar
• Kimura M, Higuchi S. (2011). Genetics of alcohol dependence. Psychiatr Clin Neurosci 65:213–25.
   PubMed Web of Science ®Google Scholar
• Knights KM, Rowland A, Miners JO. (2013). Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 76:587–602.
   PubMed Web of Science ®Google Scholar
• Lee SL, Shih HT, Chi YC, et al. (2011). Oxidation of methanol, ethylene glycol, and isopropanol with human alcohol dehydrogenases and the inhibition by ethanol and 4-methylpyrazole. Chem Biol Interact 191:26–31.
   PubMed Web of Science ®Google Scholar
• Lenz D, Jübner M, Bender K, et al. (2011). Inhibition of 1,4-butanediol metabolism in human liver in vitro. Naunyn Schmiedebergs Arch Pharmacol 383:647–54.
   PubMed Web of Science ®Google Scholar
• Murai T, Takakusa H, Nakai D, et al. (2014). Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica 44:996–1008.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Schaefer O, Kawakami H, et al. (2012). Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83–92.
   PubMed Web of Science ®Google Scholar
• Parés X, Farrés J, Kedishvili N, Duester G. (2008). Medium- and short-chain dehydrogenase/reductase gene and protein families: Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. Cell Mol Life Sci 65:3936–49.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Senzer N, Mekhail T, et al. (2011). A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754–64.
   PubMed Web of Science ®Google Scholar
• Sandberg M, Yasar U, Strömberg P, et al. (2002). Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54:423–9.
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. (2013). Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Murakami H, Nishina T, et al. (2013). The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 24:1653–9.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Goldberg JM, Dubois SG, et al. (2012). Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118:5894–902.
   PubMed Web of Science ®Google Scholar
• Walsh JS, Reese MJ, Thurmond LM. (2002). The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 142:135–54.
   PubMed Web of Science ®Google Scholar
• Zahir H, Kastrissons H, Carothers M, et al. (2012). Exposure-response relationship to assess the risk of neutropenia in patients with hepatocellular carcinoma (HCC) treated with tivantinib. Ann Oncol 23:738.
   Google Scholar